A Phase IIa Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of 14 Days' Treatment With Four Oral Doses of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis
Latest Information Update: 07 Oct 2019
At a glance
- Drugs Pretomanid (Primary) ; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- 30 Sep 2019 Results of Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients using data from PA-824-CL-007 and PA-824-CL-010 studies, published in the Antimicrobial Agents and Chemotherapy
- 24 May 2010 Results have been published in Antimicrobial Agents and Chemotherapy.
- 28 Oct 2008 Primary endpoint 'Bacteriological response rate' has been met.